An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results… read more.
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy… read more.
A next-generation total-body PET/CT scanner can produce diagnostic-quality images in as little as one minute of scanning, according to research presented today at the 39th Annual Congress of… read more.
Johnson & Johnson announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six… read more.
According to information published on the European Medicines Agency (EMA) website, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of… read more.
Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in… read more.
Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic solid tumors with HER2 expression (immunohistochemistry [IHC]… read more.
The American Society of Hematology (ASH) released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. ASH’s new guidelines recommend expanded molecular testing, early transplant… read more.
AnaptysBio, Inc. a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, announced that GSK has received U.S…. read more.
Actinium Pharmaceuticals, Inc. , a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1… read more.
In an analysis of data on adolescents and young adults with breast cancer, lower income and younger age were linked with delays in care. The analysis published by… read more.
Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
